#Coronavirus Disease Research #References (AMEDEO, May 2 '26)

 

Ann Intern Med

1. COTTON D
   "Never More Than 15 Feet From the Respirator": Housestaff Research During the 1955 Boston Polio Epidemic.
   Ann Intern Med. 2026 Apr 28. doi: 10.7326/ANNALS-25-05440.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. WALLS G, McGrath L, Herdman MT, Campbell AJ, et al
   Patient-reported perceptions, experiences and preferences around intravenous and oral antibiotics for the treatment of Staphylococcus aureus bacteremia: a descriptive qualitative study.
   Clin Infect Dis. 2025 Sep 24:ciaf522. doi: 10.1093.
   PubMed         Abstract available
   
   
3. SHAH AB, Lindsey KN, Zambrano LD, Free RJ, et al
   Multisystem inflammatory syndrome in children (MIS-C), United States, 2023-2024.
   Clin Infect Dis. 2026 Apr 27:ciag259. doi: 10.1093.
   PubMed         Abstract available
   
   
4. RAMACHANDRAN V, Onukwube Okaro J, Prasad N, Park S, et al
   Epidemiology of Pediatric Invasive Group A Streptococcal Infections in 10 U.S. States, 2004-2023.
   Clin Infect Dis. 2026 Apr 27:ciag284. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. SHAH P, Pischel L, Sack B, Km AB, et al
   Air Conditioning, Ventilation, and Respiratory Virus Transmission Potential in South India.
   Int J Infect Dis. 2026 Apr 22:108724. doi: 10.1016/j.ijid.2026.108724.
   PubMed         Abstract available
   
   
6. REICH S
   Re: Petersen E, Hviid AP. Inosine pranobex as a treatment of SARS-CoV-2? Int J Infect Dis. 2026.
   Int J Infect Dis. 2026 Apr 24:108736. doi: 10.1016/j.ijid.2026.108736.
   PubMed        
   
   
7. TERLIESNER N, Lesniowski D, Unterwalder N, von Bernuth H, et al
   RSV as an independent driver of a subsequent influenza epidemic in Berlin before and after the COVID-19 pandemic.
   Int J Infect Dis. 2026 Apr 28:108741. doi: 10.1016/j.ijid.2026.108741.
   PubMed         Abstract available
   
   
8. YAO C, Dong Y, Zou X, Alhaskawi A, et al
   Severe acute limb ischemia in patients with COVID-19: a single-center case series.
   Int J Infect Dis. 2026 Apr 28:108740. doi: 10.1016/j.ijid.2026.108740.
   PubMed         Abstract available
   
   

   
   Intensive Care Med

9. VENKATESAN N, Shah FA, Bain W, Yang Z, et al
   Risk heterogeneity within hypoinflammatory acute respiratory failure: continuous probabilities identify high-risk patients masked by binary classification.
   Intensive Care Med. 2026 Apr 27. doi: 10.1007/s00134-026-08406.
   PubMed         Abstract available
   
   

   
   J Infect

10. KIM HK, Jo S, Min KD, Cho SI, et al
    Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in Patients With Cancer: Evidence From a Nationwide Target Trial Emulation.
    J Infect. 2026 Apr 28:106753. doi: 10.1016/j.jinf.2026.106753.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. LARSEN L, Bistrup C, Sorensen SS, Jorgensen CS, et al
    Torque Teno Virus Viral Load as a Predictive Marker of Serotype-Specific Antibody Response Following the 13-Valent Conjugated Pneumococcal Vaccine in Adult Kidney Transplant Recipients: A Cohort Study.
    J Med Virol. 2026;98:e70949.
    PubMed         Abstract available
    
    
12. WEISS JJ, Messina J, Saullo J, Li Y, et al
    Respiratory Viral Infections Following CD19 CAR T-Cell Therapy.
    J Med Virol. 2026;98:e70941.
    PubMed         Abstract available
    
    

    
    J Virol

13. GUO D, Yu S, Ma K, Tao H, et al
    Concanavalin A targets phylogenetically conserved N-linked glycans on coronavirus spike proteins for broad-spectrum antiviral activity.
    J Virol. 2026 Apr 27:e0167925. doi: 10.1128/jvi.01679.
    PubMed         Abstract available
    
    
14. NASIR A, Lee D, Avena LE, Berrueta DM, et al
    Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants.
    J Virol. 2026 Apr 27:e0022526. doi: 10.1128/jvi.00225.
    PubMed         Abstract available
    
    
15. CHEN L, Su H, Shang W, Nie T, et al
    SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.
    J Virol. 2026 Apr 27:e0222325. doi: 10.1128/jvi.02223.
    PubMed         Abstract available
    
    
16. KOTANI N, Iwasa K, Amimoto T, Yamashita C, et al
    Pseudovirus-mediated proximity labeling identifies candidate host cell membrane proteins involved in viral attachment.
    J Virol. 2026 Apr 29:e0050726. doi: 10.1128/jvi.00507.
    PubMed         Abstract available
    
    

    
    JAMA

17. ANDERER S
    Most US Health Care Workers Vaccinated for Flu, Less Than Half for COVID-19.
    JAMA. 2026 May 1. doi: 10.1001/jama.2026.2126.
    PubMed        
    
    

    
    Lancet

18. SHANKAR-HARI M, Ming D, Mendelson M, Rupali P, et al
    The Lancet Commission on Sepsis: transforming sepsis care and outcomes.
    Lancet. 2026 Apr 22:S0140-6736(26)00648-3. doi: 10.1016/S0140-6736(26)00648.
    PubMed        
    
    

    
    Science

19. BOHM R, Schneider A, Betsch C, Lilleholt L, et al
    CDC communication undermines trust in vaccines.
    Science. 2026;392:475-477.
    PubMed         Abstract available
    

#Coronavirus Disease Research #References (by AMEDEO, April 25 '26)

 

Ann Intern Med

1. FRITZ JM, Skolasky RL, Brennan G, Minick K, et al
   Effectiveness of Nonpharmacologic Treatments for Chronic Low Back Pain : A Sequential, Multiple-Assignment, Randomized Trial.
   Ann Intern Med. 2026 Apr 21. doi: 10.7326/ANNALS-25-04645.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. BAKER JV, Siegel L, Losso M, Vasudeva S, et al
   Ensitrelvir for the treatment of hospitalized adults with COVID-19: an international phase 3 randomized placebo-controlled trial.
   Clin Infect Dis. 2026 Apr 22:ciag272. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. ZHAO CY, Wang FS, Jiao YM
   SARS-CoV-2 infection disrupts the immune control status in a male HIV-1 elite controller.
   Int J Infect Dis. 2026 Apr 20:108713. doi: 10.1016/j.ijid.2026.108713.
   PubMed         Abstract available
   
   

   
   J Infect

4. BEHARIER O, Guedalia J, Sehtman-Shachar DR, Kerem L, et al
   Maternal SARS-CoV-2 Infection and Early Child Growth and Development: A Nationwide Cohort Study.
   J Infect. 2026 Apr 17:106749. doi: 10.1016/j.jinf.2026.106749.
   PubMed         Abstract available
   
   

   
   J Med Virol

5. HO SY, Liu YC, Ho SY, Chen SH, et al
   Emergence of Echovirus 11 in Severe and Neonatal Enterovirus Infections: A 9-Year Retrospective Study in Taiwan Before and After the COVID-19 Pandemic.
   J Med Virol. 2026;98:e70929.
   PubMed         Abstract available
   
   
6. AVILA JP, Park P, Singh Y, Amaral PP, et al
   Multiorgan Molecular Landscape of Severe COVID-19 Revealed by Consensus Gene Signatures and RAB8B Targeting.
   J Med Virol. 2026;98:e70932.
   PubMed         Abstract available
   
   
7. KESKIN S, Pavel STI, Sak R, Bahadori F, et al
   Modified mRNA Encoding the Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein Confers Robust Protection Against Lethal Challenge in Mice.
   J Med Virol. 2026;98:e70940.
   PubMed         Abstract available
   
   

   
   J Virol

8. SALISCH F, Muller-Ruttloff C
   Behind the membranous curtain-lipid dynamics and functions in coronaviral replication.
   J Virol. 2026 Apr 21:e0175325. doi: 10.1128/jvi.01753.
   PubMed         Abstract available
   
   
9. YANG M, Zhao Y, Guo W, Wang L, et al
   Development of a vaccine based on mRNA assembly of PEDV virus-like particle.
   J Virol. 2026 Apr 21:e0206025. doi: 10.1128/jvi.02060.
   PubMed         Abstract available
   
   
10. ZHANG K, Wang S, Kang X, Li F, et al
    Swine GBP1 restricts PDCoV replication via disrupting the replication and transcription complex formation.
    J Virol. 2026 Apr 21:e0020726. doi: 10.1128/jvi.00207.
    PubMed         Abstract available
    
    
11. ZHAO J, Tian J, Zhang L, Li Y, et al
    Coronavirus infectious bronchitis virus spike protein inhibits FUNDC1-mediated mitophagy to prevent nucleocapsid protein degradation.
    J Virol. 2026 Apr 20:e0180025. doi: 10.1128/jvi.01800.
    PubMed         Abstract available
    
    
12. MU S, Bai Y, Qiu R, Zhang F, et al
    Porcine hemagglutinating encephalomyelitis virus nucleocapsid protein targets RIG-I and IRF3 to evade IFN immunity.
    J Virol. 2026 Mar 30:e0211225. doi: 10.1128/jvi.02112.
    PubMed         Abstract available
    
    
13. ZHANG X, Li Y, Yuan J, Li Q, et al
    Metformin hydrochloride regulates glycolysis and inhibits PEDV replication by inhibition of PI3K-AKT signaling pathway.
    J Virol. 2026;100:e0014726.
    PubMed         Abstract available
    
    

    
    JAMA

14. LEFF B, Siu A, DeCherrie LV, Levine DM, et al
    Hospital at Home and Transforming US Health Care Delivery.
    JAMA. 2026 Apr 23. doi: 10.1001/jama.2026.4791.
    PubMed        
    
    
15. KUKOYI OM, Wang VS, Yao K, Cipriano CB, et al
    US State Actions Related to COVID-19 Vaccination Infrastructure and Access Amid Federal Shifts.
    JAMA. 2026 Apr 20:e265148. doi: 10.1001/jama.2026.5148.
    PubMed        
    
    

    
    Lancet Infect Dis

16. ZHANG L, Hoffmann M, Pohlmann S
    Does BA.3.2 epidemiology imply a change in SARS-CoV-2 evolution?
    Lancet Infect Dis. 2026 Apr 17:S1473-3099(26)00192.
    PubMed        
    
    

    
    N Engl J Med

17. BUTLER CC, Pinto AD, Harris V, Holmes J, et al
    Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;394:1583-1594.
    PubMed         Abstract available
    
    

    
    Nature

18. GALLO G, Di Nardo A, Lugano D, Roberts AJ, et al
    Heart-nosed bat alphacoronaviruses use human CEACAM6 to enter cells.
    Nature. 2026 Apr 22. doi: 10.1038/s41586-026-10394.
    PubMed         Abstract available
    
    
19. YAN H
    A bat coronavirus can enter human cells through a previously unknown gateway.
    Nature. 2026 Apr 22. doi: 10.1038/d41586-026-00908.
    PubMed        

#Coronavirus Disease Research #References (by AMEDEO, April 19 '26)

 

Ann Intern Med

1. ALBALOUL H, Nemer A, Saini N, Schuster MG, et al
   Infectious Diseases: What You May Have Missed in 2025.
   Ann Intern Med. 2026 Apr 14:e2600983. doi: 10.7326/ANNALS-26-00983.
   PubMed         Abstract available
   
   

   
   BMJ

2. DAVIES SR, Davies AL, Higgins JPT, Caldwell DM, et al
   Effectiveness of interventions to increase vaccine uptake: component network meta-analysis.
   BMJ. 2026;393:e087578.
   PubMed         Abstract available
   
   
3. PAGEL C
   The UK Covid-19 Inquiry lays bare the cost of delayed action for NHS staff.
   BMJ. 2026;393:s696.
   PubMed        
   
   

   
   Clin Infect Dis

4. THORPE A, Lee RA, Szymczak JE, Farrell MC, et al
   Comparing the Antimicrobial Resistance Crisis to the Coronavirus Disease 2019 Pandemic: A Randomized Public Health Messaging Experiment.
   Clin Infect Dis. 2026 Apr 8:ciag110. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Emerg Infect Dis

5. ISMAIL H, Perovic O, Mpembe R, Lowman W, et al
   Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa.
   Emerg Infect Dis. 2026;32:563-572.
   PubMed         Abstract available
   
   
6. ANDRES C, Prats-Mendez I, Midgley S, Berginc N, et al
   Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014-2024.
   Emerg Infect Dis. 2026;32:491-499.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

7. DUROCHER F, Dufresne SF, Dufresne PJ, Marchand-Senecal X, et al
   Healthcare-associated Pneumocystis jirovecii transmission in the era of universal masking and distancing.
   Infect Control Hosp Epidemiol. 2026 Apr 13:1-6. doi: 10.1017/ice.2026.10446.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

8. NGIAM JN, Yap AJ, Wee LE, Koh MCY, et al
   Parental Vaccination Status and Other Socioeconomic Determinants Shaping COVID-19 Vaccine Uptake in Children and Adolescents in Singapore.
   Int J Infect Dis. 2026 Apr 15:108686. doi: 10.1016/j.ijid.2026.108686.
   PubMed         Abstract available
   
   
9. ALI AS, Vanoli E, Smati-Lafarge M, Boudjemaa A, et al
   Computational Fluid Dynamics and Genotyping to explore Airborne Transmission of Respiratory Viruses in Hospitals.
   Int J Infect Dis. 2026 Apr 9:108697. doi: 10.1016/j.ijid.2026.108697.
   PubMed         Abstract available
   
   
10. GARDINER LE, Lozano-Rojas D, Smith N, Espley J, et al
    Investigating prognostic classifications of pre-existing multiple long-term conditions for health outcomes one-year after COVID-19 hospitalisation: a UK prospective observational study.
    Int J Infect Dis. 2026 Apr 9:108695. doi: 10.1016/j.ijid.2026.108695.
    PubMed         Abstract available
    
    

    
    Intensive Care Med

11. MYATRA SN, Nasa P, Chanchalani GP, Zimmerman JL, et al
    Gender equality and equity in intensive care: an international Delphi consensus study.
    Intensive Care Med. 2026 Apr 15. doi: 10.1007/s00134-026-08394.
    PubMed         Abstract available
    
    

    
    J Med Virol

12. MULLER V, Kolditz M, Shvachko V, Oppelt T, et al
    Effectiveness of Remdesivir on All-Cause In-Hospital Mortality in Patients With Chronic Respiratory Comorbidities Who Are Hospitalized With COVID-19 in the United States.
    J Med Virol. 2026;98:e70926.
    PubMed         Abstract available
    
    
13. CAPPARELLI E, Maggiolini D, Paschale M, Pavia C, et al
    Changes in ANA Positivity Following SARS-CoV-2 Outbreak in Lombardy Region, Italy.
    J Med Virol. 2026;98:e70927.
    PubMed         Abstract available
    
    

    
    J Virol

14. RAHEJA H, Sahu R, Ghosh T, Paul S, et al
    HuR enhances SARS-CoV-2 non-structural protein translation through the genomic 5'-UTR, by promoting polypyrimidine tract-binding protein binding.
    J Virol. 2026 Apr 16:e0027626. doi: 10.1128/jvi.00276.
    PubMed         Abstract available
    
    

    
    JAMA

15. RUBIN R
    What to Know About Cicada, or BA.3.2, the Latest SARS-CoV-2 Variant Under Monitoring.
    JAMA. 2026 Apr 17. doi: 10.1001/jama.2026.5535.
    PubMed        
    
    

    
    Life Sci

16. BARTOLOMEO CS, Lemes RMR, Morais RL, Pereria GC, et al
    Corrigendum to "SARS-CoV-2 infection and replication kinetics in different human cell types: The role of autophagy, cellular metabolism and ACE2 expression" [Life Sciences 308 (2022) 120930].
    Life Sci. 2026 Apr 9:124367. doi: 10.1016/j.lfs.2026.124367.
    PubMed        
    
    

    
    Nat Ment Health

17. HIDALGO-PADILLA L, Gogarty E, Sarkodie R, Gaughran F, et al
    Primary care consultation modality and acute mental health service use in adults.
    Nat Ment Health. 2026;4:574-581.
    PubMed         Abstract available
    
    

    
    Nature

18. STEINER C
    Almost half of traded wildlife carries disease-causing pathogens.
    Nature. 2026 Apr 9. doi: 10.1038/d41586-026-01121.
    PubMed        

#SARS-CoV-2 #vaccination and #infection elicit cross-neutralizing responses against clade 3 and 4 #sarbecoviruses

 

Abstract

Two sarbecoviruses, SARS-CoV-1 and SARS-CoV-2 that engage ACE2 through their receptor-binding domains, have caused major human outbreaks. The pandemic potential of sarbecoviruses has prompted the discovery and classification of bat and other zoonotic sarbecoviruses that are also able to use human ACE2 or ACE2 ortholog receptors for infection. However, the current human immunological landscape reactive to these SARS-CoV-2-related viruses is not well profiled. Using a panel of pseudotyped lentiviruses expressing only spike proteins, we assess serum neutralization activity against clade 3 and 4 (also designated as clade 1c) receptor binding domain classified sarbecoviruses in a cohort who received a primary series of COVID-19 mRNA vaccines as well as individuals before and after infection with BA.5 or XBB.1.5 variants. Detectable neutralizing responses against clade 3 and 4 sarbecoviruses are observed in both vaccinees and convalescents and are comparable in magnitude to titers against SARS-CoV-2 variants. Infection with XBB.1.5 increases neutralization titers against SARS-CoV-2 variants as well as against clade 3 and 4 sarbecoviruses. Collectively, our findings suggest that the current immunologic landscape of vaccination and infection may confer some level of immunity against a variety of clade 3 and 4 sarbecoviruses, which should inform future pandemic response and pan-sarbecovirus countermeasure efforts.

Source: 

Link: https://www.nature.com/articles/s41467-026-71662-y

____

#Coronavirus Disease Research #References (by AMEDEO, April 11 '26)

 

Emerg Infect Dis

1. NILLES EJ, Paulino CT, Vasquez M, Duke W, et al
   Acute Febrile Illness Surveillance for Estimating Population Immunity, Dominican Republic, 2021.
   Emerg Infect Dis. 2026;32.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

2. LEUCCI AC, Sasdelli E, Caselli L, Fabbri E, et al
   Healthcare-associated infections in Italian long-term care facilities: a machine learning analysis of a 12-month cohort.
   Infect Control Hosp Epidemiol. 2026 Apr 8:1-8. doi: 10.1017/ice.2026.10413.
   PubMed         Abstract available
   
   
3. NG I, Kave B, Paynter C, Bodas C, et al
   Speech intelligibility and hearing acuity assessments of N95/P2 respirator with under-mask elastic band beard cover.
   Infect Control Hosp Epidemiol. 2025;46:1127-1133.
   PubMed         Abstract available
   
   
4. MILNER AL, Eckstein EC, Donskey CJ
   Does one size fit all for contact precautions implementation? Impact of requiring use of gloves and gowns for every room entry on personnel time, personal protective equipment costs, and carbon footprint.
   Infect Control Hosp Epidemiol. 2025;46:1161-1163.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. CHOI Y, Bae GH, Jeon J, Yoon J, et al
   Short-Term Mortality and the Impact of Disability Type Following COVID-19 Among Individuals with Disabilities: A Population-Based Study.
   Int J Infect Dis. 2026 Apr 4:108677. doi: 10.1016/j.ijid.2026.108677.
   PubMed         Abstract available
   
   
6. OGAWA K, Xu YS, Shimakawa Y, Chowell G, et al
   Secondary SARS-CoV-2 Transmission from Childcare Workers versus Teachers in School-Associated Screening Events, Okinawa, Japan, January-March 2022.
   Int J Infect Dis. 2026 Apr 2:108672. doi: 10.1016/j.ijid.2026.108672.
   PubMed         Abstract available
   
   
7. UNSELD M, Sturtzel B, Meyer AL, Blaise M, et al
   Real-world effectiveness and antibody responses of BNT162b2 vaccination in long-term care residents: a retrospective case-control study.
   Int J Infect Dis. 2026 Apr 2:108682. doi: 10.1016/j.ijid.2026.108682.
   PubMed         Abstract available
   
   
8. PETERSEN E, Hviid AP
   Inosine pranobex as a treatment of SARS-CoV2?
   Int J Infect Dis. 2026 Dec 31:108657. doi: 10.1016/j.ijid.2026.108657.
   PubMed        
   
   

   
   Intensive Care Med

9. GODOLPHIN PJ, Fisher DJ, Bradbury CA, Murthy S, et al
   Intermediate- versus prophylactic-dose heparin for hospitalised patients with COVID-19: an updated meta-analysis of randomised trials.
   Intensive Care Med. 2026 Apr 7. doi: 10.1007/s00134-025-08128.
   PubMed        
   
   

   
   J Infect

10. LOMHOLT FK, Valentiner-Branth P, Nielsen RT, Slotved HC, et al
    A real-time register-based surveillance system for non-invasive and invasive pneumococcal disease.
    J Infect. 2026 Apr 4:106744. doi: 10.1016/j.jinf.2026.106744.
    PubMed         Abstract available
    
    

    
    J Virol

11. JEFFERSON V, Endlich-Frazier A, Letko M
    Exploring coronavirus cell entry with functional viromics.
    J Virol. 2026 Apr 6:e0172825. doi: 10.1128/jvi.01728.
    PubMed         Abstract available
    
    
12. CHEN N, Kleine-Weber H, Alkharsah K, Winkler M, et al
    Q1020R in the spike proteins of MERS-CoV from Arabian camels confers resistance against soluble human DPP4.
    J Virol. 2026 Apr 6:e0028226. doi: 10.1128/jvi.00282.
    PubMed         Abstract available
    
    

    
    Life Sci

13. CHEN W, Ji MC, Jung E, Shin JS, et al
    Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation.
    Life Sci. 2026 Mar 31:124357. doi: 10.1016/j.lfs.2026.124357.
    PubMed         Abstract available
    
    

    
    Science

14. PHILLIPS KA, Horn DM, Califf RM
    Diagnostics investments and disease burden.
    Science. 2026;392:151-153.
    PubMed         Abstract available
    
    
15. KHAN S, Zhang R, Khan A, Shah A, et al
    We survived COVID-19-Are we ready for Nipah?
    Science. 2026;392:157-158.
    PubMed        

#Species - and #variant - specific #ACE2 compatibility shapes #SARS-CoV-2 #spillover potential in North American #cervids

 

Abstract

Free-ranging white-tailed deer (WTD) are established SARS-CoV-2 reservoirs, but the susceptibility of other cervid species remains unclear. Here we integrate receptor analysis, structural modeling, and field surveillance to assess SARS-CoV-2 susceptibility across North American cervids. We identify species- and variant-specific differences in ACE2–spike compatibility. Elk ACE2 exhibits weak binding to the ancestral strain (Wuhan-Hu-1) and Delta spike receptor-binding domains (RBDs), likely due to a unique K31N substitution. In contrast, it shows stronger binding to Alpha, Beta, Gamma, and Omicron RBDs containing N501Y. Biophysical assays, gel filtration chromatography, and cryo-EM confirm stable complex formation between elk ACE2 and Alpha RBD, but not RBD from the ancestral strain. Despite weak binding, elk ACE2 supports viral entry and replication in vitro. However, surveillance revealed limited evidence of infection in the United States, contrasting with widespread WTD transmissions. These findings demonstrate that ACE2 compatibility alone is insufficient to predict reservoir potential and provide a framework for assessing species susceptibility to emerging coronaviruses.

Source: 

Link: https://www.nature.com/articles/s41467-026-71623-5

____

#Coronavirus Disease Research #References (by AMEDEO, April 4 '26)

 

Ann Intern Med

1. REIS G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, et al
   The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial.
   Ann Intern Med. 2026 Mar 31. doi: 10.7326/ANNALS-25-03959.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. NADIG N, Bhimraj A, Cawcutt K, Chiotos K, et al
   2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.
   Clin Infect Dis. 2026 Apr 1:ciaf681. doi: 10.1093.
   PubMed         Abstract available
   
   
3. SHUMAKER AH, Bhimraj A, Bedimo R, Cheng VC, et al
   2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.
   Clin Infect Dis. 2026 Apr 1:ciaf680. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. HOSSAIN MS, Goyal R, Martin NK, DeGruttola V, et al
   Machine Learning and Probabilistic Approaches for Forecasting Infectious Disease Transmission and Cases.
   Int J Infect Dis. 2026 Mar 30:108674. doi: 10.1016/j.ijid.2026.108674.
   PubMed         Abstract available
   
   
5. VESELY D, Capek V, Sanca O, Beran J, et al
   Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry.
   Int J Infect Dis. 2026 Dec 31:108519. doi: 10.1016/j.ijid.2026.108519.
   PubMed         Abstract available
   
   

   
   J Med Virol

6. GARCIA-VILLALBA J, Hurtado-Navarro L, Angosto-Bazarra D, Baroja-Mazo A, et al
   The Open Reading Frame 7b of the SARS-CoV-2 Disperse Trans-Golgi and Activate the NLRP3 Inflammasome.
   J Med Virol. 2026;98:e70894.
   PubMed         Abstract available
   
   
7. THEO CH, Sam IC, Chan YF
   The Diverse Roles of Heparan Sulfate in RNA Virus Infections: Insights From Enterovirus A71, Severe Acute Respiratory Syndrome Coronavirus 2, and Chikungunya Virus.
   J Med Virol. 2026;98:e70888.
   PubMed         Abstract available
   
   

   
   J Virol

8. MOU C, Liu M, Xiang Y, Lin C, et al
   SADS-CoV NS3 induces apoptosis by blocking the formation of Bcl-xL-BAK complex.
   J Virol. 2026 Mar 31:e0021626. doi: 10.1128/jvi.00216.
   PubMed         Abstract available
   
   
9. KONG W, Zhang J, Song Y, Song J, et al
   Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity.
   J Virol. 2026 Mar 30:e0027026. doi: 10.1128/jvi.00270.
   PubMed         Abstract available
   
   
10. GUO X, Zhao X, He J, Lu Y, et al
    E3 ubiquitin ligase NEDD4 inhibits PEDV infection through ubiquitination and degradation of the viral primase NSP8.
    J Virol. 2026 Mar 30:e0215625. doi: 10.1128/jvi.02156.
    PubMed         Abstract available
    
    
11. XIU R, Wang Y, Cai W, Wang Q, et al
    Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M(pro) inhibitors.
    J Virol. 2026 Mar 30:e0007626. doi: 10.1128/jvi.00076.
    PubMed         Abstract available
    
    
12. CHENG D, Luo Z, Ning W, Heath SL, et al
    Systemic translocation of Staphylococcus aureus promotes autoimmunity: implications in autoantibody-mediated poor immune reconstitution from antiretroviral therapy in HIV.
    J Virol. 2026 Apr 3:e0196525. doi: 10.1128/jvi.01965.
    PubMed         Abstract available
    
    
13. POZHIDAEVA A, Hoch JC, Pustovalova Y
    The DMV pore-forming TM2-Y region of SARS-CoV-2 nsp3 exhibits structural conservation beyond the coronavirus family.
    J Virol. 2026 Apr 3:e0203825. doi: 10.1128/jvi.02038.
    PubMed         Abstract available
    
    

    
    JAMA

14. ANDERER S
    US COVID-19 Deaths May Have Been Underreported, Study Finds.
    JAMA. 2026 Apr 3. doi: 10.1001/jama.2026.1032.
    PubMed        
    
    

    
    Lancet Infect Dis

15. CAMICI M, Piano Mortari E, Del Duca G, Cimini E, et al
    Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings.
    Lancet Infect Dis. 2026 Mar 31:S1473-3099(26)00063.
    PubMed         Abstract available
    
    
16. WALKER MK, Yek C, Sarzynski S, Warner S, et al
    Survival trends in patients with difficult-to-treat, antibiotic-resistant, Gram-negative infections in the era of next-generation antibiotics in the USA: a retrospective cohort study.
    Lancet Infect Dis. 2026 Mar 25:S1473-3099(26)00020.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

17. MEGHANI M, Garacci Z, Razzaghi H, de Perio MA, et al
    Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel - United States, 2024-25 Respiratory Virus Season.
    MMWR Morb Mortal Wkly Rep. 2026;75:164-171.
    PubMed         Abstract available
    
    

    
    Science

18. STONE R
    U.S. blockade hits Cuba's health care and science.
    Science. 2026;392:8-9.
    PubMed         Abstract available
    
    
19. FAN Q, Mei J, Li T, Zang C, et al
    A high-throughput selection system for fast-acting covalent protein drugs.
    Science. 2026 Apr 2:eadv3081. doi: 10.1126/science.adv3081.
    PubMed         Abstract available
    

#Coronavirus Disease Research #References (by AMEDEO, March 28 '26)

 

Emerg Infect Dis

1. FENG PI, Phares CR, Pratt R, Self JL, et al
   Tuberculosis before and during COVID-19 Pandemic, United States, 2010-2023.
   Emerg Infect Dis. 2026;32:388-396.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

2. SCHWEI RJ, Ikenberry H, Griffin M, Werner N, et al
   Optimizing antimicrobial stewardship during operational upheaval: lessons in resiliency from the COVID-19 pandemic.
   Infect Control Hosp Epidemiol. 2026 Mar 26:1-10. doi: 10.1017/ice.2026.10415.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. JANG S, Cheong C, Choi WS, Kim KH, et al
   Transitioning to Routine Immunization: Cost-Effectiveness of a National COVID-19 Vaccination Program for Older Adults in South Korea.
   Int J Infect Dis. 2026 Mar 23:108585. doi: 10.1016/j.ijid.2026.108585.
   PubMed         Abstract available
   
   
4. XU Y, Kwek EC, Gene KTE, Conceicao EP, et al
   Trends and Outcomes of COVID-19 Hospital Admissions 'For' vs. 'With' COVID-19 in Singapore: A Retrospective Cohort Study using the SingHealth COVID-19 Registry.
   Int J Infect Dis. 2026 Mar 19:108559. doi: 10.1016/j.ijid.2026.108559.
   PubMed         Abstract available
   
   

   
   Intensive Care Med

5. WEISS SL, Peters MJ, Oczkowski SJW, Belley-Cote E, et al
   Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026.
   Intensive Care Med. 2026 Mar 23. doi: 10.1007/s00134-026-08360.
   PubMed         Abstract available
   
   

   
   J Med Virol

6. WU W, Rippee-Brooks MD, Adam A, Weinstein KH, et al
   Variant-Specific tRNA-Derived Fragments Induced By Severe Acute Respiratory Syndrome Coronavirus 2: Implications for Disease Outcome Differentiation.
   J Med Virol. 2026;98:e70881.
   PubMed         Abstract available
   
   

   
   J Virol

7. CHEN C, Su G, Wang Y, Xiong Y, et al
   PEX19 restricts porcine deltacoronavirus replication through farnesylation-dependent and -independent mechanisms.
   J Virol. 2026 Mar 24:e0209725. doi: 10.1128/jvi.02097.
   PubMed         Abstract available
   
   
8. BAYUROVA E, Kostyushev D, Tikhonov A, Chulanov V, et al
   Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics.
   J Virol. 2026 Mar 23:e0007726. doi: 10.1128/jvi.00077.
   PubMed         Abstract available
   
   

   
   Lancet Infect Dis

9. BIJUKCHHE SM, Marchevsky NG, Kibengo F, Sharma AK, et al
   Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.
   Lancet Infect Dis. 2026 Mar 19:S1473-3099(26)00053.
   PubMed         Abstract available
   
   

#Evolution and viral properties of the #SARS-CoV-2 #BA32 #subvariant

 

Abstract

The SARS-CoV-2 Omicron subvariant BA.3.2 descends from BA.3. It emerged two years after BA.3 ceased to circulate and differs by 39 spike mutations from BA.3. Similar to BA.2.86, which circulated at low levels before giving rise to JN.1, BA.3.2 shows a low but persistent circulation globally. Here, we characterize the phylogenetic origin, infection in cell culture, and neutralization of BA.3.2 using live virus and blood plasma samples collected in South Africa at different stages of the Covid-19 pandemic. Like the Omicron BA.2.86 subvariant, we find that BA.3.2 likely emerged in Southern Africa. We also find that an 871 bp deletion removed ORF7 and ORF8. In H1299-ACE2 cells, BA.3.2 has lower cytotoxicity measured as plaque area compared to ancestral SARS-CoV-2 but similar to the co-circulating LP.8.1 Omicron subvariant with which it also shares similar replication and infection focus size. BA.3.2 and LP.8.1 exhibit complete escape from neutralization from pre-Omicron collected plasma samples, have low levels of neutralization by plasma collected in 2024, and higher neutralization by plasma collected in 2025, with BA.3.2 showing moderately lower neutralization than LP.8.1. The emergence of long branch subvariants like BA.3.2 without intermediates likely indicates that unmonitored persistent infections continue to drive large evolutionary shifts in this virus.

Source: 

Link: https://academic.oup.com/ve/article/12/1/veag011/8490867

____

Mild #SARS-CoV-2 #maternal #infection in mice induces transient offspring #neurodevelopmental aberrance

 

Significance

The rising global numbers of SARS-CoV-2 infections highlight the need to assess potential neurodevelopmental and psychiatric impact in children born to infected mothers. Human cohorts have provided conflicting conclusions, while mouse studies have focused on moderate-to-severe infection despite most infections in pregnant women being mild or asymptomatic. Our study shows that mild, respiratory tract–restricted SARS-CoV-2 infection in pregnant mice was sufficient to cause placental inflammation and transient changes in offspring brain gene expression, without altering gross brain structure or behavior under our experimental conditions. These findings suggest that soluble factors induced by maternal respiratory infection mediate placental inflammation and changes in offspring brain gene expression during the fetal and neonatal periods, which resolve in later childhood.

Abstract

Maternal viral infection during pregnancy has been identified as a risk factor for psychiatric disorders and neurodevelopmental abnormalities in offspring. With cumulative SARS-CoV-2 infections now numbering in the hundreds of millions globally, there is a need to evaluate the effects of maternal SARS-CoV-2 infection on offspring brain development and behavior. We developed a mouse model of mild COVID-19 during pregnancy in which SARS-CoV-2 infection is restricted to the respiratory tract. Infected mothers did not show weight loss or changes in litter size, but did exhibit detectable local and systemic immune responses, including placental inflammation. Characterization of the offspring’s cerebral cortex revealed transcriptomic changes in the fetus at E15 and on postnatal day 5 (P5), but no gross alterations in cytoarchitecture, synaptic density, or microglial abundance. We did not detect any significant changes in open-field or novel object recognition tests in P50 offspring born to SARS-CoV-2-infected dams. These findings suggest that mild maternal respiratory SARS-CoV-2 infection induces soluble factors that mediate placental inflammation and transient cerebral cortex alterations in offspring that resolve by later childhood.

Source: 

Link: https://www.pnas.org/doi/abs/10.1073/pnas.2518294123?af=R

____

#Coronavirus Disease Research #References (by AMEDEO, March 21 '26)

 

Am J Obstet Gynecol

1. REGAN AK, Rowe SL, Birchfield J, Liu J, et al
   Adherence to Recommended Antiviral Treatment Guidelines for COVID-19 and Influenza during Pregnancy.
   Am J Obstet Gynecol. 2026 Mar 16:S0002-9378(26)00155.
   PubMed        
   
   
2. BONIFACE ER, Alvergne A, Darney BG, Benhar E, et al
   Menstrual cycle patterns during acute and long COVID-19 infection among a cohort of individuals with regular menstrual cycles.
   Am J Obstet Gynecol. 2026 Mar 11:S0002-9378(26)00132.
   PubMed        
   
   

   
   BMJ

3. SCANDRETT K, Sitch AJ, Barratt J, Brettell EA, et al
   Accuracy of glomerular filtration rate estimation based on creatinine and cystatin C for monitoring moderate chronic kidney disease in adults: prospective, longitudinal cohort study.
   BMJ. 2026;392:e085005.
   PubMed         Abstract available
   
   
4. LANG K
   How does covid-19 affect the skin?
   BMJ. 2026;392:s264.
   PubMed        
   
   

   
   Graefes Arch Clin Exp Ophthalmol

5. HEIDER MR, Tian TE, Lee AM, Tailor PD, et al
   Private equity in ophthalmology: geographic trends reveal urban-rural disparities in acquisitions and satellite expansion.
   Graefes Arch Clin Exp Ophthalmol. 2026 Jan 14. doi: 10.1007/s00417-025-07017.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

6. MALAKOOTI SK, Abboud M, Murphy JE, Singer NG, et al
   Autoimmune Disease is Associated with Heightened Long COVID Risk but Prior Immunization is Protective.
   Int J Infect Dis. 2026 Mar 17:108540. doi: 10.1016/j.ijid.2026.108540.
   PubMed         Abstract available
   
   
7. LI A, Wu Y, Zeng X, Zhang X, et al
   Regional divergence in pediatric tuberculosis and implications for achieving End TB targets, 2013-2023.
   Int J Infect Dis. 2026 Mar 17:108564. doi: 10.1016/j.ijid.2026.108564.
   PubMed         Abstract available
   
   
8. FAROKHNIA A, Faro LK, Tian Y, Frischknecht L, et al
   Extended Nirmatrelvir-Ritonavir for Persistent COVID-19: Systematic Review with Individual Patient Data.
   Int J Infect Dis. 2026 Mar 17:108558. doi: 10.1016/j.ijid.2026.108558.
   PubMed         Abstract available
   
   

   
   J Infect

9. PEREZ-MAZZALI M, Perez-Cozar F, Cal-Sabater P, Rybakowska P, et al
   Persistent T cell phenotypic alterations and early innate immune dysregulation as potential biomarkers of Long COVID.
   J Infect. 2026 Mar 17:106731. doi: 10.1016/j.jinf.2026.106731.
   PubMed         Abstract available
   
   
10. MAZARAKIS N, Toh ZQ, Neal E, Nguyen C, et al
    Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia.
    J Infect. 2026;92:106727.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. WANG M, He J, Chen S, Yuan W, et al
    Involucrasins Potentially Prevents SARS-CoV-2 Infection via Inhibiting Caspase-1 Signaling in Several Variants.
    J Med Virol. 2026;98:e70874.
    PubMed         Abstract available
    
    

    
    J Virol

12. ZHAI Y, Ma Y, Liu C, Zhang Y, et al
    PEDV regulates trans-mammary epithelial migration of T cells in a CCR10/CCL28-dependent manner.
    J Virol. 2026 Mar 20:e0002426. doi: 10.1128/jvi.00024.
    PubMed         Abstract available
    
    
13. ADAM A, Wu W, Jones MC, Hao H, et al
    Respiratory syncytial virus infection induces heterologous protection against SARS-CoV-2 through gammadelta T cell-mediated trained immunity and the activation of SARS-CoV-2-reactive mucosal T cells.
    J Virol. 2026 Mar 18:e0165825. doi: 10.1128/jvi.01658.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

14. SHAKYA M, Ma KC, Hughes LJ, Smith C, et al
    Early Detection and Surveillance of the SARS-CoV-2 Variant BA.3.2 - Worldwide, November 2024-February 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:130-137.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

15. ZOU C, Mankowski W, Pantalone L, Horng H, et al
    Transformer-based Fusion of Longitudinal Multimodal Radiomic Features from Chest Radiography and CT in COVID-19.
    Radiol Artif Intell. 2026 Mar 18:e240218. doi: 10.1148/ryai.240218.
    PubMed         Abstract available
    

Early #Detection and #Surveillance of the #SARS-CoV-2 #Variant #BA32 — Worldwide, November 2024–February 2026 (US CDC, MMWR, March 19 '26)

 

Summary

-- What is already known about this topic?

- CDC tracks SARS-CoV-2 variants internationally using digital public health surveillance and in the United States using genomic surveillance, including wastewater and traveler-based surveillance. 

- The highly divergent SARS-CoV-2 variant BA.3.2 was first detected in a respiratory sample collected on November 22, 2024, in South Africa.

-- What is added by this report?

- As of February 11, 2026, BA.3.2 had been reported in 23 countries. 

- Detections began increasing in September 2025. 

- In the United States, BA.3.2 was detected in nasal swabs from four travelers, three airplane wastewater samples, clinical samples from five patients, and 132 wastewater samples from 25 U.S. states.

-- What are the implications for public health practice?

- Monitoring the spread of BA.3.2 provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from a previous infection or vaccination.

Abstract

The SARS-CoV-2 variant BA.3.2 was first identified in South Africa on November 22, 2024. BA.3.2 has approximately 70–75 substitutions and deletions in the gene sequence of the spike protein relative to JN.1 and its descendant, LP.8.1, the antigens used in the 2025–26 COVID-19 vaccines. CDC is using a multimodal SARS-CoV-2 genomic surveillance approach to monitor the emergence and spread of BA.3.2 and other SARS-CoV-2 variants internationally and within the United States. The first U.S. BA.3.2 detection occurred on June 27, 2025, through CDC’s Traveler-Based Genomic Surveillance program in a participant traveling to the United States from the Netherlands. The first U.S. detection of BA.3.2 in a clinical specimen collected from a patient was reported on January 5, 2026. As of February 11, 2026, BA.3.2 had been detected in voluntarily self-collected nasal swabs from four U.S. travelers, clinical samples from five patients, three airplane wastewater samples, and 132 wastewater surveillance samples from 25 states. BA.3.2 has been reported by at least 23 countries. SARS-CoV-2 continues to cause substantial morbidity and mortality worldwide. BA.3.2 mutations in the spike protein have the potential to reduce protection from a previous infection or vaccination. Continued genomic surveillance is needed to track SARS-CoV-2 evolution and determine its potential effect on public health.

Source: 

Link: https://www.cdc.gov/mmwr/volumes/75/wr/mm7510a1.htm?s_cid=OS_mm7510a1_e&ACSTrackingID=USCDC_921-DM153709&ACSTrackingLabel=Week%20in%20MMWR%3A%20Vol.%2075%2C%20March%2019%2C%202026&deliveryName=USCDC_921-DM153709

____

#Coronavirus Disease Research #References (by AMEDEO, March 14 '26)

 

Antiviral Res

1. ZHANG J, Deng S, Zhang M, Wu X, et al
   Porcine epidemic diarrhea virus infection activates SREBP2 and induces RORgamma expression to enhance cholesterol biosynthesis and virus replication.
   Antiviral Res. 2026 Mar 6:106391. doi: 10.1016/j.antiviral.2026.106391.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. KHADER K, Haroldsen C, Stevens V, Visnovsky L, et al
   Estimating changes in facility MRSA infection rates due to changes in MRSA precaution policy.
   Clin Infect Dis. 2026 Mar 13:ciag176. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. LUGTU EJ, Iv DYP, Cabunoc MH, Bautista JL, et al
   Prevalence of Post-COVID Symptoms Across Variants of Concern and Follow-up Periods: A Systematic Review and Meta-Analysis.
   Int J Infect Dis. 2026 Mar 10:108522. doi: 10.1016/j.ijid.2026.108522.
   PubMed         Abstract available
   
   
4. TANG X, Memedi M, Sun S, Hiyoshi A, et al
   Machine learning-based 4-domain framework for evaluating COVID-19 policy responses: a counterfactual analysis of 27 European OECD countries.
   Int J Infect Dis. 2026 Mar 10:108528. doi: 10.1016/j.ijid.2026.108528.
   PubMed         Abstract available
   
   
5. YONGHAO G, Yuting T, Huixin L, Minghua S, et al
   Characteristics of Respiratory Co-infections in Influenza-like Illness during the Post-COVID-19 Era.
   Int J Infect Dis. 2026 Mar 5:108507. doi: 10.1016/j.ijid.2026.108507.
   PubMed         Abstract available
   
   
6. YANG M, Zhou M
   Re-evaluation of Treatment Strategies and Drug Development for Mycoplasma Pneumoniae.
   Int J Infect Dis. 2026 Feb 28:108510. doi: 10.1016/j.ijid.2026.108510.
   PubMed         Abstract available
   
   
7. KATUMBA H, Migisha R, Komakech A, Wenani D, et al
   Delayed patient isolation and associated factors during the mpox outbreak in Uganda, July-December 2024.
   Int J Infect Dis. 2026;164:108346.
   PubMed         Abstract available
   
   

   
   J Infect

8. ZHANG H, Kang Z, Zhang Y, Yang Y, et al
   Evolutionary dynamics and global spread of macrolide-resistant Bordetella pertussis during the post-pandemic pertussis resurgence.
   J Infect. 2026 Mar 7:106718. doi: 10.1016/j.jinf.2026.106718.
   PubMed         Abstract available
   
   

   
   J Med Virol

9. YOVEL G, Packard JE, Wang JC, Maya S, et al
   Neonatal CNS Human Parechovirus Infections in Western Pennsylvania in the 2024 Season.
   J Med Virol. 2026;98:e70870.
   PubMed         Abstract available
   
   
10. CAO J, Yang G, Cui T, Qin J, et al
    Complement Hyperactivation Is Mediated by Alternative and Lectin Pathways During Early Phase of Severe Vaccination-Omicron BA.5 Infection.
    J Med Virol. 2026;98:e70863.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

11. MALONEY P, Reeves EL, Wielgosz K, Price AM, et al
    Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:116-123.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by AMEDEO, March 7 '26)

 

Ann Intern Med

1. LIM SY, Lee J, Chang E, Kwon JS, et al
   Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-04883.
   PubMed         Abstract available
   
   

   
   Antiviral Res

2. ZUO X, Xiao X, Dong X, Wang J, et al
   Direct-acting antivirals and beyond: emerging approaches to targeting viral RNA and ribonucleoprotein complexes.
   Antiviral Res. 2026;249:106383.
   PubMed         Abstract available
   
   
3. RUDRAMURTHY GR, Gudla CS, Harisha R, Selvam V, et al
   FNDR-11124, a broad-spectrum small molecule inhibitor of viral RNA polymerase, restricts replication of SARS-CoV-2 and Influenza virus in vitro and in vivo.
   Antiviral Res. 2026 Mar 2:106382. doi: 10.1016/j.antiviral.2026.106382.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

4. RIERA MT, Prato R, Perez-Rubio A, Echave-Sustaeta JM, et al
   Burden of respiratory syncytial virus among older adults with an acute respiratory infection: a prospective study in six European countries.
   Clin Infect Dis. 2026 Mar 6:ciag146. doi: 10.1093.
   PubMed         Abstract available
   
   
5. TAN CS, Anjan S, Ariza-Heredia EJ, Magana F, et al
   IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal RSV infections in immunocompromised patients.
   Clin Infect Dis. 2026 Mar 2:ciag117. doi: 10.1093.
   PubMed         Abstract available
   
   
6. NELLORE A, Goepfert P, Tan CS, Bajema K, et al
   IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19, Influenza, and RSV infections in immunocompromised patients.
   Clin Infect Dis. 2026 Mar 2:ciag114. doi: 10.1093.
   PubMed         Abstract available
   
   
7. GOEPFERT P, Katz MJ, Kaul D, Sharma T, et al
   IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal Influenza infections in immunocompromised patients.
   Clin Infect Dis. 2026 Feb 28:ciag116. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

8. NYGREN M, Dahlgren HM, Gustavsson L, Snygg-Martin U, et al
   Temporal association and seasonal variation of respiratory viruses and invasive group A streptococcal infections in Western Sweden, a 15-year analysis across pre- and postpandemic periods.
   Int J Infect Dis. 2026 Mar 3:108517. doi: 10.1016/j.ijid.2026.108517.
   PubMed         Abstract available
   
   
9. YEZLI S, Bonanni P, Dinleyici EC, Divyesh T, et al
   Invasive Meningococcal Disease Rebound in Older Adults Post-COVID-19 Pandemic: A Targeted Literature and Surveillance Review.
   Int J Infect Dis. 2026 Feb 27:108502. doi: 10.1016/j.ijid.2026.108502.
   PubMed         Abstract available
   
   

   
   J Virol

10. LI S, Liu DX
    Interaction of coronavirus E protein with BRD2 plays important regulatory roles in viral replication and induction of pro-inflammatory response.
    J Virol. 2026 Mar 3:e0220125. doi: 10.1128/jvi.02201.
    PubMed         Abstract available
    
    

    
    N Engl J Med

11. GABET A, Bernard C, Zureik M
    Updated Evidence Base for Covid-19, RSV, and Influenza Immunizations.
    N Engl J Med. 2026;394:10.
    PubMed        

#Coronavirus Disease Research #References (by AMEDEO, Feb. 28 '26)

 

Am J Respir Crit Care Med

1. MENDEZ R, Gonzalez-Jimenez P, Latorre A, Piqueras M, et al
   The Long-term Pneumonia Mortality Index. An International Multicenter Derivation and Validation Study for Patients with Community-Acquired Pneumonia.
   Am J Respir Crit Care Med. 2026 Feb 21:aamag060. doi: 10.1093.
   PubMed         Abstract available
   
   
2. GAERTNER VD, Ramin-Wright L, Waldmann AD, Belting C, et al
   The first breaths after birth-early lung function in healthy term infants.
   Am J Respir Crit Care Med. 2026 Jan 30:aamag008. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Ann Intern Med

3. QASEEM A, Obley AJ, Harrod CS, Wilt TJ, et al
   COVID-19 Vaccines for 2025-2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
   Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05026.
   PubMed         Abstract available
   
   
4. 
   Annals Video Summary - COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised.
   Ann Intern Med. 2026 Feb 24:e2600306VS. doi: 10.7326/ANNALS-26-00306.
   PubMed        
   
   
5. 
   Summary for Patients: COVID-19 Vaccines for 2025-2026.
   Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05026.
   PubMed        
   
   
6. DOBRESCU A, Pinte L, Sharifan A, Gadinger A, et al
   Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
   Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05044.
   PubMed         Abstract available
   
   

   
   Antiviral Res

7. ZHANG T, Wang ZL, Li XY, Luo RH, et al
   Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m(6)A enzymatic activity.
   Antiviral Res. 2026 Feb 19:106376. doi: 10.1016/j.antiviral.2026.106376.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

8. NELLORE A, Bajema K, Belden K, Blumberg D, et al
   IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19 infections in immunocompromised patients.
   Clin Infect Dis. 2026 Feb 25:ciag115. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

9. ALVES COSTA SILVA C, Pinheiro Bomfim A, Dutra Medeiros J, de Jesus Silva J, et al
   Corrigendum to "Nasal microbiota and clinical features in acute flu-like illness: COVID-19 status and long COVID follow-up" [International Journal of Infectious Diseases 162 (2026) 108196 https://doi.org/10.1016/j.ijid.2025.108196].
   Int J Infect Dis. 2026;165:108441.
   PubMed        
   
   

   
   J Infect

10. ORDONEZ-MENA JM, Radin JM, Hoang U, Araujo AB, et al
    Epidemiology of virologically confirmed RSV, influenza and COVID-19 in adults in England, 2023-2024: Primary Care Observational Study of Acute Respiratory Infection (ObservatARI).
    J Infect. 2026 Feb 21:106714. doi: 10.1016/j.jinf.2026.106714.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. PHUONG LE UN, Chou RH, Lin CS, Lai HC, et al
    SARS-CoV-2 Main Protease Activates ERK1/2 Signaling to Facilitate MEG2-STAT3-Mediated Suppression of ACE2.
    J Med Virol. 2026;98:e70855.
    PubMed         Abstract available
    
    
12. 
    EXPRESSION OF CONCERN: The Emergence, Spread and Vanishing of a French SARS-CoV-2 Variant Exemplifies the Fate of RNA Virus Epidemics and Obeys the Mistigri Rule.
    J Med Virol. 2026;98:e70842.
    PubMed        
    
    

    
    J Virol

13. NOORUZZAMAN M, Butt SL, Rani R, Ye C, et al
    The ORF6 accessory protein contributes to SARS-CoV-2 virulence and pathogenicity in the naturally susceptible feline model of infection.
    J Virol. 2026 Feb 27:e0064425. doi: 10.1128/jvi.00644.
    PubMed         Abstract available
    
    

    
    Nature

14. VENTER M, Manuguerra JC, Watson JM, Fischer TK, et al
    COVID's origins: what we do and don't know.
    Nature. 2026;650:829-833.
    PubMed